TEL AVIV, Israel, Aug. 2, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News) today announced the signing of a memorandum of understanding (MOU) for the future distribution of SkinScan 650, the medical device for detection and diagnosis of skin cancer, signed by the wholly owned subsidiary, Skin Cancer Scanning Ltd. with a Russian Corp, active in the medical device field. This follows the company's recent announcement that it is targeting new market opportunities in this emerging region.
The new MOU covers the regulatory certification required by the Russian regulator, regional sales, marketing and distribution of SkinScan 650, SCS's non-invasive, point-of-care system to detect and identify different types of skin cancers.
Russia and the CIS are among the fastest-growing healthcare markets globally. Total population of the region exceeds 270 million people, and there is increasing demand for advanced medical technologies. According to health care experts, one of the most serious problems with cancer treatment in Russia is a very low rate of early detection. Typically, the disease is diagnosed at very advanced stages when treatment options are less effective and more costly.
"This MOU is an important element of our growth strategy for this region," said mBeach CEO Yossi Biderman. "Our product, though still a prototype, will be ideally suited, once the industrial prototype is approved by the Russian regulator, to meet the growing demand for better cancer detection. We are very excited at the potential of this market and see this MOU as a stepping stone to entering additional, attractive markets around the world."
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment